期刊文献+

聚合物-药物结合物递药系统的研究进展 被引量:6

The Development of Drug Delivery System Based on Polymer-Drug Conjugates
原文传递
导出
摘要 聚合物-药物结合物作为新型的递药系统,在药学领域应用广泛。它能够有效地提高药物的水溶性,改善其体内外行为,增强治疗指数并保护药物分子免遭降解。文章主要讨论了聚合物载体、化学连接链和给药途径这3大设计因素对聚合物-药物结合物递药系统的影响,并以新兴的聚合物载体为分类标准对该领域的最新研究进展进行了概述,以期为后续研究提供参考。 Polymer-drug conjugates as a novel drug delivery system have been widely used in the field of pharmaceutics. It can effectively increase the aqueous solubility of parent drugs,improve their in vitro and in vivo behaviors,enhance the therapeutic efficiency and protect drug molecules against degradation. In this review,the important factors including polymer selection,chemical linker and administration routes that determine the rational design of polymer-drug conjugates were mainly discussed. Moreover,using novel polymer carriers as classification criterion,the recent achievements in the field of polymer-drug conjugates have been summarized in order to guide the further studies.
作者 李宁 刘晓燕
出处 《药物生物技术》 CAS 2015年第4期357-361,共5页 Pharmaceutical Biotechnology
关键词 聚合物-药物结合物 聚合物材料 药物载体 递药系统 肿瘤 注射给药 Polymer-drug conjugates Polymer material Drug carrier Drug delivery system Tumor Injection administration
  • 相关文献

参考文献32

  • 1Haag R, Kratz F. Polymer therapeutics:concepts and applications [ J ]. A ngew Chem Int Ed, 2006,45 ( 8 ) : 1198 - 1215.
  • 2Jatzkewitz H. Peptamin ( glycyl-L-leucyl-mescaline ) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine ( mescaline ) [ J ]. Z NatugCorseh, 1955,10 : 27 -31.
  • 3Perez H L, Cardarelli P M, Deshpande S, et al. Antibody-drug conjugates : current status and future directions [ J ]. Drug Discov Today,2014,19(7) :869-881.
  • 4Ringsdorf 14. Structure and properties of pharmacologically active polymers [ J ]. J Polym Sci Polym Syrup, 1975,51 ( 1 ) :135-153.
  • 5Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability andthe EPR effect in macromolecular therapeutics : a review [ J ]. J Control Rel,2000,65( 1 ) :271-284.
  • 6Duncan R. Polymer conjugates as anticancer nanomedicines [ J ]. Nature Reviews Cancer,2006,6(9) :688-701.
  • 7Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: phannacokinetic and pharmacodynamic perspectives [ J]. Curr Pharm Biotechnol, 2003,4(5 ) :283-302.
  • 8Etrych T, ubr V, Strohahn J, et al. HPMA copolymer-doxorubicin conjugates:The effects of molecular weight and architecture on biodistribution and in vivo activity [ J ]. J Control Rel, 2012,164 (3) :346-354.
  • 9Markovsky E, Baabur-Cohen H, Eldar-Boock A,et al. Administra- tion, distribution, metabolism and elimination of polymer thera- peutics[J]. J Control Rel,2012 ,161 (2) :446-460.
  • 10Vercauteren R, Bruneel D, Schacht E,et al. Effect of the chemical modification of dextran on the degradation by dextranase [J ]. J Bioact Compatible Polym, 1990,5 ( 1 ) :4-15.

二级参考文献126

共引文献13

同被引文献129

  • 1闫雪霏,杨晔,尹登科.两亲性多糖自组装胶束给药系统研究进展[J].中国生化药物杂志,2014,34(4):174-178. 被引量:6
  • 2华何与,杨运高,张红栓.论气虚血瘀与肿瘤转移[J].中国中医基础医学杂志,2005,11(8):564-565. 被引量:16
  • 3夏朝红,戴奇,房韦,陈和生.几种多糖的红外光谱研究[J].武汉理工大学学报,2007,29(1):45-47. 被引量:109
  • 4Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect[J]. Adv Drug Deliver Rev, 2011, 63(3): 136-151.
  • 5Dosio F, Stella B, Arpicco S, et al. Macromolecules as taxane delivery systems[J]. Expert Opin Drug Del, 2011, 8(1): 33-55.
  • 6Wang Y, Yang X, Yang J, et al. Serf-assembled nanopartieles of methotrexate conjugated O-carboxymethyl ehitosan: Preparation, characterization and drug release behavior in vitro[J]. Carbohyd Polym, 2011, 86(4): 1665-1670.
  • 7Luo Q, Wang P, Miao Y, et al. A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromoleeular carrier for sustained release[J]. CarbohydPolym, 2012, 87(4): 2642-2647.
  • 8Bassi P, Volpe A, D' agostino D, et al. Paclitaxel-hyaluronic acid for iutravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: Results of a phase I study[J]. J Urology, 2011, 185(2): 445-449.
  • 9Danhauser-Riedl S, Hausmann E, Schick HI), et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD- 70, DOX-OXD)[J].InvestNewI)rug, 1993, 11(2): 187-195.
  • 10Luo XM, Chen MH, Zhang Y, et al. Pharmacokinetics and antitumor efficacy of micelles assembled from muhiarmed amphiphilic copolymers with drug conjugates in comparison with drug-encapsulated micelles[J]. EurJ Pharm Biopharm, 2016, 98: 9-19.

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部